FVC variable (L) | Comparison | LS mean differences in changes from baseline | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Abediterol 0.625 μg (N = 67) | Abediterol 2.5 μg (N = 66) | Abediterol 5 μg (N = 66) | Abediterol 10 μg (N = 67) | ||||||||||
LS mean | 95 % CI | p- value | LS mean | 95 % CI | p-value | LS mean | 95 % CI | p-value | LS mean | 95 % CI | p-value | ||
Normalised AUC0-12 at Day 1 | vs placebo | 0.227 | 0.169, 0.284 | <0.0001 | 0.280 | 0.222, 0.337 | <0.0001 | 0.301 | 0.243, 0.358 | <0.0001 | 0.347 | 0.289, 0.405 | <0.0001 |
vs indacaterol | 0.010 | −0.047, 0.068 | 0.7258 | 0.063 | 0.05, 0.121 | 0.0323 | 0.084 | 0.027, 0.142 | 0.0044 | 0.130 | 0.072, 0.188 | <0.0001 | |
Normalised AUC12-24 at Day 1 | vs placebo | 0.182 | 0.114, 0.249 | <0.0001 | 0.308 | 0.201, 0.376 | <0.0001 | 0.352 | 0.285, 0.420 | <0.0001 | 0.386 | 0.319, 0.454 | <0.0001 |
vs indacaterol | −0.026 | −0.094, 0.042 | 0.4471 | 0.100 | 0.031, 0.166 | 0.0045 | 0.144 | 0.076, 0.212 | <0.0001 | 0.178 | 0.110, 0.247 | <0.0001 | |
Normalised AUC0-24 at Day 1 | vs placebo | 0.208 | 0.153, 0.263 | <0.0001 | 0.294 | 0.239, 0.349 | <0.0001 | 0.332 | 0.276, 0.387 | <0.0001 | 0.369 | 0.313, 0.424 | <0.0001 |
vs indacaterol | −0.007 | −0.063, 0.048 | 0.7996 | 0.079 | 0.023, 0.135 | 0.0058 | 0.117 | 0.061, 0.172 | <0.0001 | 0.154 | 0.098, 0.209 | <0.0001 | |
Peak FVC at Day 1 | vs placebo | 0.152 | 0.035, 0.270 | 0.0110 | 0.191 | 0.074, 0.309 | 0.0015 | 0.201 | 0.083, 0.318 | 0.0009 | 0.244 | 0.127, 0.361 | <0.0001 |
vs indacaterol | 0.013 | −0.104, 0.131 | 0.8219 | 0.052 | −0.065, 0.170 | 0.3829 | 0.062 | −0.056, 0.179 | 0.3024 | 0.105 | −0.012, 0.222 | 0.0795 |